Literature DB >> 35949296

Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass.

Masatoshi Kudo1.   

Abstract

Entities:  

Keywords:  Anti-PD-1/PD-L1 antibody; Anti-VEGF antibody; Hepatocellular carcinoma; Noninflamed tumor

Year:  2022        PMID： 35949296      PMCID： PMC9218634          DOI： 10.1159/000524977

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   12.430


× No keyword cloud information.
  22 in total

Review 1.  Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases.

Authors:  Peter Carmeliet; Rakesh K Jain
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

2.  T-cell activation under hypoxic conditions enhances IFN-gamma secretion.

Authors:  Jessica Roman; Tirumalai Rangasamy; Jia Guo; Siva Sugunan; Nida Meednu; Gopinath Packirisamy; Larissa A Shimoda; Amit Golding; Gregg Semenza; Steve N Georas
Journal:  Am J Respir Cell Mol Biol       Date:  2009-04-16       Impact factor: 6.914

3.  OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma.

Authors:  Akihisa Ueno; Yohei Masugi; Ken Yamazaki; Mina Komuta; Kathryn Effendi; Yutaka Tanami; Hanako Tsujikawa; Akihiro Tanimoto; Shigeo Okuda; Osamu Itano; Yuko Kitagawa; Sachio Kuribayashi; Michiie Sakamoto
Journal:  J Hepatol       Date:  2014-06-16       Impact factor: 25.083

4.  The Wnt/β-catenin and PI3K/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation.

Authors:  Yue Song; Zhao-Xia Li; Xi Liu; Rui Wang; Li-Wei Li; Qingyu Zhang
Journal:  Tumour Biol       Date:  2017-07

5.  Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors.

Authors:  Gregory T Motz; Stephen P Santoro; Li-Ping Wang; Tom Garrabrant; Ricardo R Lastra; Ian S Hagemann; Priti Lal; Michael D Feldman; Fabian Benencia; George Coukos
Journal:  Nat Med       Date:  2014-05-04       Impact factor: 53.440

6.  VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.

Authors:  Thibault Voron; Orianne Colussi; Elie Marcheteau; Simon Pernot; Mevyn Nizard; Anne-Laure Pointet; Sabrina Latreche; Sonia Bergaya; Nadine Benhamouda; Corinne Tanchot; Christian Stockmann; Pierre Combe; Anne Berger; Franck Zinzindohoue; Hideo Yagita; Eric Tartour; Julien Taieb; Magali Terme
Journal:  J Exp Med       Date:  2015-01-19       Impact factor: 14.307

Review 7.  Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Cancers (Basel)       Date:  2020-04-27       Impact factor: 6.639

Review 8.  Clinical Significance of the Duality of Wnt/β-Catenin Signaling in Human Hepatocellular Carcinoma.

Authors:  Tomoko Aoki; Naoshi Nishida; Masatoshi Kudo
Journal:  Cancers (Basel)       Date:  2022-01-17       Impact factor: 6.639

Review 9.  Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.

Authors:  Shu-Jin Li; Jia-Xian Chen; Zhi-Jun Sun
Journal:  Cancer Commun (Lond)       Date:  2021-06-17
View more
  2 in total

1.  Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2022-07-27       Impact factor: 12.430

2.  Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150.

Authors:  Takuya Sho; Goki Suda; Yoshiya Yamamoto; Ken Furuya; Masaru Baba; Koji Ogawa; Akinori Kubo; Yoshimasa Tokuchi; Qingjie Fu; Zijian Yang; Megumi Kimura; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Akihisa Nakamura; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Tomofumi Takagi; Jun Ito; Tomoe Kobayashi; Takuto Miyagishima; Naoya Sakamoto
Journal:  Cancers (Basel)       Date:  2022-08-15       Impact factor: 6.575
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.